Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Seroprevalence Study of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

NCT06311708 is registered in ClinicalTrials.gov with Tenaya Therapeutics as lead sponsor.

NCT NCT06311708
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06311708 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Seroprevalence Study of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
Lead sponsor
Tenaya Therapeutics
Phase
Observational
Overall status
Recruiting
Start date
January 31, 2023
Completion date
July 11, 2030
Enrollment
200 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

arrhythmogenic right ventricular cardiomyopathy